These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22627739)

  • 1. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis.
    Gianelli U; Vener C; Bossi A; Cortinovis I; Iurlo A; Fracchiolla NS; Savi F; Moro A; Grifoni F; De Philippis C; Radice T; Bosari S; Lambertenghi Deliliers G; Cortelezzi A
    Mod Pathol; 2012 Sep; 25(9):1193-202. PubMed ID: 22627739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis.
    Lekovic D; Gotic M; Perunicic-Jovanovic M; Vidovic A; Bogdanovic A; Jankovic G; Cokic V; Milic N
    Med Oncol; 2014 Mar; 31(3):869. PubMed ID: 24500865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis.
    Vener C; Fracchiolla NS; Gianelli U; Calori R; Radaelli F; Iurlo A; Caberlon S; Gerli G; Boiocchi L; Deliliers GL
    Blood; 2008 Feb; 111(4):1862-5. PubMed ID: 18029552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.
    Gill H; Leung AY; Chan CC; Lau JS; Chan C; Yip SF; Liu H; Kho B; Mak V; Lee HK; Lin SY; Lau CK; Kwong YL
    Hematology; 2016 Jan; 21(1):10-8. PubMed ID: 26292161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM
    Ann Hematol; 2006 Apr; 85(4):226-32. PubMed ID: 16421727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.
    Kröger N; Zabelina T; Alchalby H; Stübig T; Wolschke C; Ayuk F; von Hünerbein N; Kvasnicka HM; Thiele J; Kreipe HH; Büsche G
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):812-5. PubMed ID: 24589549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients.
    Gianelli U; Fiori S; Cattaneo D; Bossi A; Cortinovis I; Bonometti A; Ercoli G; Bucelli C; Orofino N; Bulfamante G; Iurlo A
    Histopathology; 2017 Dec; 71(6):897-908. PubMed ID: 28710830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis].
    Chen M; Xu ZF; Xu JQ; Li B; Zhang PH; Qin TJ; Zhang Y; Wang JY; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):876-880. PubMed ID: 27801320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
    Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
    Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
    Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
    Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
    Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
    Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
    Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European consensus on grading bone marrow fibrosis and assessment of cellularity.
    Thiele J; Kvasnicka HM; Facchetti F; Franco V; van der Walt J; Orazi A
    Haematologica; 2005 Aug; 90(8):1128-32. PubMed ID: 16079113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is pre-fibrotic myelofibrosis and how should it be managed in 2018?
    Curto-Garcia N; Ianotto JC; Harrison CN
    Br J Haematol; 2018 Oct; 183(1):23-34. PubMed ID: 30328618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow fibrosis in newly diagnosed multiple myeloma and its correlation with clinicopathological factors.
    Hu X; Dai X; Guo X; Jiang X; Li Y; Zhao H; Lu J; Li X; Jin M
    Diagn Pathol; 2024 Jul; 19(1):99. PubMed ID: 39026319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival of patients with myelofibrosis in the last decade: Single-center experience.
    Masarova L; Bose P; Pemmaraju N; Daver NG; Sasaki K; Chifotides HT; Zhou L; Kantarjian HM; Estrov Z; Verstovsek S
    Cancer; 2022 Apr; 128(8):1658-1665. PubMed ID: 35077575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the volume ratio of bone marrow affected by fibrosis: a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia.
    Buesche G; Georgii A; Duensing A; Schmeil A; Schlue J; Kreipe HH
    Hum Pathol; 2003 Apr; 34(4):391-401. PubMed ID: 12733122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J; Kvasnicka HM
    Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes.
    Buesche G; Teoman H; Wilczak W; Ganser A; Hecker H; Wilkens L; Göhring G; Schlegelberger B; Bock O; Georgii A; Kreipe H
    Leukemia; 2008 Feb; 22(2):313-22. PubMed ID: 18033321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
    Kuykendall AT; Talati C; Padron E; Sweet K; Sallman D; List AF; Lancet JE; Komrokji RS
    Am J Hematol; 2019 Jan; 94(1):87-92. PubMed ID: 30390311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.